No connection

Search Results

OSUR

BEARISH
$3.24 Live
OraSure Technologies, Inc. · NASDAQ
Target $5.0 (+54.3%)
$2.08 52W Range $3.82

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 16, 2026
Market cap
$223.97M
P/E
N/A
ROE
-18.3%
Profit margin
-59.8%
Debt/Equity
0.04
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
OSUR presents a stark contrast between a fortress-like balance sheet and a deteriorating business model. While the Piotroski F-Score of 6/9 indicates stable financial health and the company maintains exceptional liquidity (Current Ratio 6.58) with negligible debt, the operational metrics are alarming. Revenue has contracted by 28.5% YoY, and profit margins are deeply negative at -59.76%. Despite trading at a significant discount to book value (P/B 0.67), the lack of growth and consistent earnings misses suggest a value trap.

Key Strengths

Extremely low Debt/Equity ratio (0.04)
Exceptional liquidity with a Current Ratio of 6.58
Trading below book value (P/B 0.67)
Stable Piotroski F-Score of 6/9
Significant upside to analyst target price ($5.00)

Key Risks

Severe revenue contraction (-28.5% YoY)
Deeply negative profit and operating margins
Consistent failure to meet earnings estimates in recent quarters
Long-term price erosion (5Y change -67.6%)
Catastrophic YoY EPS growth (-216.7%)
AI Fair Value Estimate
Based on comprehensive analysis
$3.8
+17.3% above current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
37
Weak
Value
60
Future
15
Past
25
Health
85
Dividend
0
AI Verdict
Value Trap
Key drivers: Strong Balance Sheet, Revenue Collapse, Negative Margins
Confidence
80%
Value
60/100

P/B suggests undervaluation, but the lack of earnings removes traditional valuation anchors.

Positives
  • P/B of 0.67 suggests asset undervaluation
Watchpoints
  • Negative earnings make P/E irrelevant
Future
15/100

Severe contraction in both top and bottom lines indicates a failing growth trajectory.

Positives
No standout positives identified.
Watchpoints
  • -28.5% Revenue Growth
  • -216.7% EPS Growth
Past
25/100

Long-term value destruction despite short-term technical bounces.

Positives
  • Recent 1Y price recovery (+10.6%)
Watchpoints
  • -67.6% 5Y return
Health
85/100

The balance sheet is the only strong pillar of the company.

Positives
  • Low Debt/Equity
  • High Current Ratio
  • Piotroski F-Score 6/9
Watchpoints
No urgent risks highlighted.
Dividend
0/100

Non-dividend paying stock.

Positives
No standout positives identified.
Watchpoints
  • No dividend payments

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$3.24
Analyst Target
$5.0
Upside/Downside
+54.3%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for OSUR and closest competitors.

Updated 2026-04-15
OSU
OraSure Technologies, Inc.
Primary
5Y
-67.6%
3Y
-52.3%
1Y
+10.6%
6M
+5.9%
1M
+3.5%
1W
+5.2%
MDW
MediWound Ltd.
Peer
5Y
-51.4%
3Y
+35.6%
1Y
+6.4%
6M
-3.1%
1M
+6.5%
1W
+6.8%
MGN
MacroGenics, Inc.
Peer
5Y
-88.9%
3Y
-46.5%
1Y
+173.2%
6M
+111.6%
1M
+15.7%
1W
+9.1%
CVR
CVRx, Inc.
Peer
5Y
-70.1%
3Y
-7.4%
1Y
-27.5%
6M
-4.1%
1M
+6.5%
1W
-11.5%
LUC
Lucid Diagnostics Inc.
Peer
5Y
-89.1%
3Y
-5.9%
1Y
+7.6%
6M
+8.5%
1M
-6.6%
1W
+13.3%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-6.89
PEG Ratio
N/A
P/B Ratio
0.67
P/S Ratio
1.95
EV/Revenue
0.33
EV/EBITDA
-0.66
Market Cap
$223.97M

Profitability

Profit margins and return metrics

Profit Margin -59.76%
Operating Margin -61.1%
Gross Margin 41.9%
ROE -18.3%
ROA -9.57%

Growth

Revenue and earnings growth rates

Revenue Growth -28.5%
Earnings Growth N/A
Q/Q Revenue Growth -28.53%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.04
Low debt
Current Ratio
6.58
Strong
Quick Ratio
5.57
Excellent
Cash/Share
$2.88

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
41.0%
Op. Margin
-63.0%
Net Margin
-72.1%
Total Assets
$0.4B
Liabilities
$0.1B
Equity
$0.3B
Debt/Equity
0.18x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
110%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-06
$N/A
2026-02-25
$-0.19
-24.8% surprise
2025-11-05
$-0.13
+13.9% surprise
2025-08-05
$-0.19
-26.2% surprise

Healthcare Sector Comparison

Comparing OSUR against 421 companies in the Healthcare sector (25 bullish, 134 neutral, 262 bearish)
Return on Equity (ROE)
-18.3%
This Stock
vs
-100.15%
Sector Avg
-81.7% (Below Avg)
Profit Margin
-59.76%
This Stock
vs
-13.63%
Sector Avg
+338.5% (Superior)
Debt to Equity
0.04
This Stock
vs
3.22
Sector Avg
-98.8% (Less Debt)
Revenue Growth
-28.5%
This Stock
vs
121.05%
Sector Avg
-123.5% (Slower)
Current Ratio
6.58
This Stock
vs
4.55
Sector Avg
+44.7% (Stronger)

Similar Companies

Peer comparison within the same industry

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

BOYD STEVEN KYLE
Director
Stock Award
2026-03-26
5,246 shares · $16,249
MCGRATH KENNETH J
Chief Financial Officer
Buy
2026-03-20
32,300 shares · $94,600
EGLINTON MANNER CARRIE
Chief Executive Officer
Buy
2026-03-20
32,300 shares · $94,597
MCGRATH KENNETH J
Chief Financial Officer
Buy
2026-03-13
22,021 shares · $66,030
EGLINTON MANNER CARRIE
Chief Executive Officer
Buy
2026-03-13
22,022 shares · $66,033
MCGRATH KENNETH J
Chief Financial Officer
Stock Award
2026-03-02
115,162 shares
EGLINTON MANNER CARRIE
Chief Executive Officer
Stock Award
2026-03-02
484,496 shares
ANTHONY MICHELE MARIE
Officer
Stock Award
2026-03-02
57,165 shares
KENNY JOHN P
Director
Stock Award
2025-12-17
10,286 shares · $25,304
GAGLIANO NANCY J
Director
Buy
2025-11-28
2,100 shares · $4,982
BOYD STEVEN KYLE
Director
Stock Award
2025-10-28
34,632 shares
Insider transactions can signal confidence or concerns about company prospects

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
NONE
2 analysts
Stephens & Co.
2025-11-12
Maintains
Equal-Weight Equal-Weight

Past News Coverage

Recent headlines mentioning OSUR from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile